Renalytix (GB:RENX)
LSE:RENX
RENX Stock Chart & Stats
5.90 p
0.99 p(8.62%)
At close: 4:00 PM EST
5.90 p
0.99 p(8.62%)
Day’s Range― - ―
52-Week Range1.90 p - 15.50 p
Previous CloseN/A
Volume11.59K
Average Volume (3M)10.03M
Market Cap
£8.52M
Enterprise Value26.40M
Total Cash (Recent Filing)£9.63M
Total Debt (Recent Filing)£8.21M
Price to Earnings (P/E)―
Beta0.08
Next Earnings
Nov 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding437,018,680
10 Day Avg. Volume3,807,103
30 Day Avg. Volume10,033,489
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)-1.38
Price to Sales (P/S)3.23
P/FCF Ratio-0.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary AI + Biomarker TestRenalytix’s KidneyIntelX pairs biomarkers with AI-driven algorithms, a structural competitive advantage that supports differentiated clinical value, higher switching costs, and potential payor interest. This platform approach can sustain adoption and deepen integrations with health systems over months to years.
Improving Revenue And Gross MarginRevenue growth and a large gross margin improvement indicate improving unit economics for the test. If sustained, higher margins imply the business model can scale profitably as volumes increase, reducing the dependence of operating leverage on continual funding over the medium term.
Lower Debt And Improving Cash TrajectoryModest absolute debt and a meaningful reduction in cash burn year-over-year show improving financial discipline and lower near-term refinancing pressure. This trend increases runway optionality and supports continued commercialization efforts if management maintains cost control.
Bears Say
Negative Shareholders' EquityNegative equity is a structural weakness that constrains capital flexibility, limits debt capacity, and often forces equity raises. Over the medium term this can dilute existing holders, complicate strategic partnerships, and increase financing costs, impacting sustainable growth execution.
Sustained Cash Burn RequiredSignificant negative operating and free cash flow indicates ongoing reliance on external funding to sustain commercialization and R&D. Continued cash burn risks operational disruption or dilution if revenue scale or reimbursement milestones are delayed, limiting long-term independence.
Tiny Revenue Base Vs Large LossesDespite growth, revenues are still minimal relative to fixed costs and result in very large net losses. This structural mismatch means break-even is distant absent sustained volume gains or material expense reductions, making self-funded scaling unlikely in the near term.
Renalytix News
RENX FAQ
What was Renalytix’s price range in the past 12 months?
Renalytix lowest share price was 1.90 p and its highest was 15.50 p in the past 12 months.
What is Renalytix’s market cap?
Renalytix’s market cap is £8.52M.
When is Renalytix’s upcoming earnings report date?
Renalytix’s upcoming earnings report date is Nov 03, 2026 which is in 209 days.
How were Renalytix’s earnings last quarter?
Renalytix released its earnings results on Mar 26, 2026. The company reported -0.016 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.016 p.
Is Renalytix overvalued?
According to Wall Street analysts Renalytix’s price is currently Overvalued.
Does Renalytix pay dividends?
Renalytix does not currently pay dividends.
What is Renalytix’s EPS estimate?
Renalytix’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Renalytix have?
Renalytix has 437,018,680 shares outstanding.
What happened to Renalytix’s price movement after its last earnings report?
Renalytix reported an EPS of -0.016 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 6.818%.
Which hedge fund is a major shareholder of Renalytix?
Currently, no hedge funds are holding shares in GB:RENX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Renalytix
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.
Technical Analysis
EKF Diagnostics Holdings
―
Genedrive
―
Oxford BioDynamics
―
Proteome Sciences
―
Verici Dx Plc
―
Options Prices
Currently, No data available
---